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Abstract
Background: The insulin-like growth factor 1 (IGF1) signaling axis plays a major role in tumorigenesis. In a previous
experiment, we chronically treated mice with several agonists of the IGF1 receptor (IGF1R). We found that chronic
treatment with insulin analogues with high affinity towards the IGF1R (IGF1 and X10) decreased the mammary
gland tumor latency time in a p53R270H/+WAPCre mouse model. Frequent injections with insulin analogues that
only mildly activated the IGF1R in vivo (glargine and insulin) did not significantly decrease the tumor latency time
in this mouse model.
Methods: Here, we performed next-generation RNA sequencing (40 million, 100 bp reads) on 50 mammary gland
tumors to unravel the underlying mechanisms of IGF1R-promoted tumorigenesis. Mutational profiling of the
individual tumors was performed to screen for treatment-specific mutations. The transcriptomic data were used to
construct a support vector machine (SVM) classifier so that the phenotypic characteristics of tumors exposed to the
different insulin analogue treatments could be predicted. For translational purposes, we ran the same classifiers on
transcriptomic (micro-array) data of insulin analogue-exposed human breast cancer cell lines. Genome-scale
metabolic modeling was performed with iMAT.
Results: We found that chronic X10 and IGF1 treatment resulted in tumors with an increased and sustained
proliferative and invasive transcriptomic profile. Furthermore, a Warburg-like effect with increased glycolysis was
observed in tumors of the X10/IGF1 groups and, to a lesser extent, also in glargine-induced tumors. A metabolic
flux analysis revealed that this enhanced glycolysis programming in X10/IGF1 tumors was associated with increased
biomass production programs. Although none of the treatments induced genetic instability or enhanced
mutagenesis, mutations in Ezh2 and Hras were enriched in X10/IGF1 treatment tumors.
Conclusions: Overall, these data suggest that the decreased mammary gland tumor latency time caused by
chronic IGF1R activation is related to modulation of tumor progression rather than increased tumor initiation.
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Background
The insulin-like growth factor 1 (IGF1) pathway plays a
critical role in cell growth, cell survival, and protection
from apoptosis. It is therefore not surprising that epi-
genetic and transcriptional changes in IGF1 signaling
can induce cancer development and progression [1, 2].
The administration of exogenous insulin is a com-
mon therapy for types I and II diabetes. New insulin-
like molecules have small modifications of the insulin
molecular structure to improve pharmacokinetic pa-
rameters of the original molecule and thereby increase
stability and temporal bioavailability. These molecular
changes possibly affect the binding affinity towards re-
ceptors including the insulin receptor (IR) or the IGF1
receptor (IGF1R). Consequently, insulin analogues
with an increased IGF1R affinity likely promote mito-
genesis [3]. Insulin X10 is an insulin analogue which
possesses a well-known increased affinity towards the
IGF1R and which consequently could promote
tumorigenesis (for this reason insulin X10 has never
entered the pharmaceutical market). Insulin glargine,
currently the most commonly prescribed insulin ther-
apy worldwide [4], also has an increased binding affin-
ity towards the IGF1R. In vivo glargine is rapidly
degraded into compounds with a lower affinity to-
wards the IGF1R. Even today there are some concerns
about the carcinogenic risk that the use of glargine
might induce [5, 6].
To study the role of IGF1R signaling in breast cancer,
we recently evaluated the tumor promoting capacity of
chronic insulin analogue treatment in a human relevant
breast cancer (p53R270H/+WAPCre) mouse model [7]. In
this model, the WAPCre system ensures mammary
gland (MG)-specific expression of the heterozygous p53
mutation, which corresponds to a mutational hotspot
often found in patients with the Li Fraumeni cancer syn-
drome [8]. Eventually, all mice spontaneously developed
these human relevant MG tumors within approximately
1 year. Chronic treatment with compounds that possess
a high affinity towards the IGF1R, IGF1 and the insulin
analogue X10, significantly decreased the tumor latency
time. Frequent injections with insulin glargine, a com-
pound that only mildly activates the IGF1R in vivo [5],
showed a similar trend but the observed tumor latency
time decrease was not significant compared to regular
insulin [7]. Systematic signaling pathway mapping of all
tumors revealed that the MAPK/ERK signaling cascade
was especially strongly activated in IGF1- and X10-
induced tumors. Although this provides some insight in
to the alternative signaling wiring in insulin analogue-
related tumors, a systematic evaluation of the genetic
modifications and consequently alterations in cellular
pathways and network biological differences of insulin
analogue-related tumors is still obscure.
In this study, to gain more insight in to the modula-
tion of tumor development and progression by chronic
IGF1R activation, we used a systematic in-depth next-
generation sequencing (NGS) approach. RNAseq ana-
lysis was performed on 50 insulin analogue-induced MG
tumors (control, insulin, IGF1, X10, and glargine treat-
ment). Overall genetic modifications were determined at
a tumor level. NGS transcriptome analysis did shed light
on the specific tumor development and progression in
relation to chronic IGF1R activation. For this, we specif-
ically evaluated the alternative modulation of the hall-
marks of cancer [9] to detect treatment-specific tumor
features.
Methods
Chronic in vivo insulin analogue treatment
Previously, we have reported the effect of insulin ana-
logues on tumor development [7]. Here, for the chronic
exposure experiment, 200 (40 mice per treatment), 8-
week-old female p53R270H/+WAPCre mice were obtained
from an in-house breeding project. The point mutation
in the tumor suppressor p53 gene corresponds to the Li
Fraumeni cancer syndrome mutational hotspot (R273H)
in humans. Every other day these mice have been
injected (subcutaneously) with either vehicle, insulin,
glargine, X10, or IGF1 until tumor development. Once
the tumors reached a size of 1 cm3 and 24 h after their
last injection the mice were sacrificed. Tumors and other
tissues were isolated. For this study, ¼ of the tumor was
stored in RNALater (Ambion, Austin, Texas) at 4 °C for
RNA isolation. A miRNA isolation kit (Macherey Nagel,
Germany) was used to isolate and purify small and large
RNA molecules in one fraction. Tumor latency time is
defined as the time (in weeks) for the tumor to form,
from the start of the experiment to the first time the
tumor was palpated.
Single insulin analogue treatment: an animal experiment
To determine the short-term effects of insulin analogue
treatment on mammary gland gene expression, a single
insulin analogue exposure experiment was performed
with 40 (4 mice per treatment/time point) female, 8-
week-old inbred FVB/NRj mice (obtained from Janvier,
rodent research models, France). This specific mouse
strain was used as it is the closest relation to the
p53R270H/+WAPCre mouse strain. Mice received a single
subcutaneous injection with either vehicle, insulin, glar-
gine, X10, or IGF1. The mice were sacrificed 1 or 6 h
after the injection, blood was collected (mini collect,
Greiner/Omnilabo), and MGs were stored in RNALater
(Ambion, USA) at 4 °C for RNA isolation. For this, a
Nucleospin RNA isolation kit (Macherey Nagel,
Germany) was used. For further technical details, please
refer to our previous publication [7].
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In vitro stimulation experiments
Next, an in vitro experiment was performed to reveal
the transcriptomic effects of insulin analogue exposure
on a human breast cancer cell line. MCF7 human breast
cancer cells with an overexpression of the IGF1R and a
stable knockdown of the IR (MCF7 IGF1R) were seeded
at 60% confluence and starved for 2 days in 5% char-
coal/dextran-treated FBS (CDFBS, Hyclone, USA) con-
taining RPMI 1640 (Gibco, USA) medium. Cells were
stimulated (with 10 nM compound) for 1 or 6 h after
which RNA was isolated using NucleoSpin® miRNA iso-
lation kit (Machery Nagel, Düren, Germany). Stimula-
tions included: insulin NPH (Insuman Basal, Sanofi
Aventis), insulin glargine (Lantus, Sanofi Aventis), insu-
lin X10 (AspB10, Novo Nordisk), and IGF1 (Increlex,
Ipsen). For more technical details about cell line gener-
ation and characterization or growth factor stimulation,
please refer to our previous publication [7].
Next-generation sequencing and gene expression analysis
For the chronic insulin analogue exposure experiment,
the quality and integrity of the RNA samples were ana-
lyzed using the bioanalyzer with an RNA nanochip. The
Ion Total RNA-Seq kit was used to process the samples.
Samples were Poly-A selected prior to library prepar-
ation. This library preparation included the cDNA syn-
thesis and purification steps with the Ion Total RNA-
Seq kit v2 (Life Technologies, UK) according to the
manufacturer’s instructions. The Ion PI Template OT2
200 Kit v3 and Ion Sequencing 200 kit v3 (both Life
Technologies) were used according to the manufac-
turer’s instructions for sequencing libraries on the PI
chip. Sequence runs were performed on the Ion Proton
Sequencer (at ServiceXS, Leiden). PI chip analysis, base
calling, and quality checks were performed using the
Torrent Server Suite. On average, 40 million reads per
sample were sequenced with an average read length of
100 base pairs. No additional trimming or filtering of
reads was performed before processing. Reads were
aligned to mouse genome build GRCm38-Ensembl using
Tophat2 (Version 2.0.10). Reads which could not be
aligned using Tophat2 were aligned in an additional
step, using Bowtie2 (Version 2-2.10) in the local, very
sensitive mode. Tophat2 and Bowtie2 aligned reads were
merged into a single .bam file for each sample before
further analysis.
Gene expression was quantified using HTSeq-Count
(Version 0.6.1) using the default options. Differential
gene expression was analyzed for compound versus
vehicle treatment and was performed using DESeq2
(Version1.2.10). For this analysis, genes with a read
count of <50 reads across samples (average of <1 read
per sample) were filtered out before the analysis. For
the estimation of individual exon expression analysis,
a RPKM table was generated with the read counts nor-
malized to library size and gene length (using DEXSeq
version 1.8.0). For the mutational profiling, the reads
(unfiltered and untrimmed) were aligned to mouse
genome build GRCm38.73-DNA primary assembly
using TMAP within the Torrent Suite version 4.0.2.
Variant calling was performed using the Torrent Suite Vari-
ant Caller version 4.0-r72612 with the settings tuned for
the detection of somatic mutations at a low stringency level.
The reference genome used was the same as that used for
read alignment—GRCm38.73. SnpEff version 3.6c was used
to filter and annotate the mutations. The list of mutations
was filtered to include only exonic mutations with a quality
score higher than 250. Several mutations are found in the
exact same position in all tumor samples, probably strain-
specific single nucleotide polymorphisms (SNPs). Known
SNPs in coding regions for the mouse strain FVB/NJ (the
strain most closely related to the p53R270H+/–WAPCre) were
downloaded from the Mouse Genome Informatics database
and these mutations were discarded from the list. Mouse
homologs of the list of human tumor driver genes [10] were
used to define the most clinically relevant mutations.
Phenotypic prediction based on transcriptomic data
To predict the phenotypic characteristics of the treat-
ments of different insulin analogues using their tran-
scriptomics, we constructed a support vector machine
(SVM) classifier. We followed a procedure similar to
that used in [11] to identify genes whose expression is
significantly associated with cancer cell migration and
proliferation across 52 breast cancer cell line data. We
then applied them to the orthologs of the mouse tran-
scriptomics data to predict the migratory and prolifera-
tive potential of 50 mouse mammary tumor samples
using LIBSVM [11].
Genome-scale metabolic modeling analysis
We estimated the metabolic fluxes that are most consist-
ent with the transcriptomics data using a computational
framework called iMAT [12]. iMAT integrates the tran-
scriptomics, as ‘soft’ constraints, by ternary partitioning
the expression to lowly (–1), mediocrely (0), and highly (1)
expressed genes. iMAT then attempts to collect the meta-
bolic states that best correspond to these cues, which con-
structs a mixed integer linear programming (MILP)
problem. We applied iMAT to the human genome-scale
metabolic model Recon1 [13] with a standard medium
condition (RPMI) in a condition-specific manner for the
five different insulin analogues treatments. The iMAT pre-
dicts (i) the biomass production rate and (ii) the metabolic
flux rates of individual metabolic reactions. The biomass
production rate is the rate at which the biomass precur-
sors are generated with appropriate proportions, and it is
incorporated in the metabolic network model as a putative
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reaction that takes cell and energetic requirements needed
to produce biomass as input [14]. With the metabolic
fluxes predicted by iMAT, we performed a pathway
enrichment analysis of differentially activated metabolic
reactions in X10/IGF1-treated cells to the remainder con-
ditions (insulin/glargine/vehicle). We selected the meta-
bolic pathways whose reactions are significantly enriched
in the up-/downregulated group using a hypergeometric
test followed by multiple hypotheses correction with the
false discovery rate (FDR) 0.05. The predicted biomass
production rate does not involve standard deviation be-
cause we focused on the metabolic states where the bio-
mass production rate is optimized (thus single-valued).
Statistical analysis
Graphpad Prism version 5.01 software was used for the
statistical analysis. All standard error bars in the graphs
represent standard deviations. Unpaired two tailed t
tests were performed to calculate significance. Multi-
experiment viewer (MeV version 4.8.1) was used for the
hierarchical clustering analysis.
Results
Genetic profiling of IGF1R signaling-mediated mammary
gland tumor formation reveals cellular processes
associated with decreased tumor latency
Previously, we chronically treated p53R270H/+WAPCre
mice with insulin and insulin analogues to study the ef-
fect of chronic IGF1R stimulation on tumorigenesis
(Fig. 1a). We found that MG tumor latency time in X10
and IGF1 (compounds with a high affinity towards the
IGF1R) treatment groups was significantly decreased
(Fig. 1b). Tumors in mice treated with glargine (an in-
sulin analogue that induces only a mild IGF1R activa-
tion in the MG) also developed earlier compared to
vehicle- and insulin-treated animals, but this trend was
not significant [7]. To further investigate this, we evalu-
ated receptor gene expression levels. We found that
gene expression levels of the insulin receptor (both the
A and B isoform; ira, irb, respectively) and insulin-like
growth factor 1 receptor (igf1r) are significantly upreg-
ulated in pre-neoplastic MG tissue of old (50 weeks on
average) p53R270H/+WAPCre mice compared to healthy
8-week-old MGs (Fig. 1c). Also, ira and igf1r levels
were slightly upregulated in MG tumors. Interestingly,
we found a significant and sevenfold downregulation of
the B-isoform of the insulin receptor in MG tumor tis-
sue compared to normal MG tissue. This effect was not
treatment specific (Fig. 1c right). Levels of igf1r were
only decreased after chronic treatment with IGF1.
These data are indicative for an involvement of INSR/
IGF1R signaling in tumor development and/or progres-
sion. However, the different receptor distributions
cannot explain the differences in tumor latency time,
since this was not a treatment-related effect.
To gain more insight in to overall differences between
various insulin analogues in tumor development and
progression, we performed RNAseq NGS of 50 tumors
(10 tumors per treatment group). We reasoned that
transcriptome analysis would shed light on the cause for
the differences in tumor latency time by chronic insulin
analogue treatment. From the 40 tumors per treatment
group, 10 epithelial to mesenchymal transition (EMT)-
like tumors were selected per treatment condition for
the transcriptome analysis; these 10 EMT tumors had a
tumor latency time that was closest to the median la-
tency time of that specific entire treatment group. The
selected tumors have been indicated with colored dots
in the Kaplan-Mayer curve (Fig. 1b). In Fig. 1d, a correl-
ation analysis shows the sample-to-sample distance. All
transcriptomics data were used to define the correlation
within and between the different treatment groups. In
spite of the relatively high variation in this in vivo ex-
periment, there was a higher correlation within each
treatment group than between the different treatment
groups. This suggests the existence of a treatment-
specific response under each treatment condition. To
define these treatment-specific responses, we focused on
four particular hallmarks of cancer (Fig. 1e) that might
have been involved in the decreased tumor latency, ei-
ther by tumor initiation or progression. These pathways
were selected in close relation to the signaling pathways
downstream of IR and IGF1R, and included: i) sustained
growth signaling; ii) tissue invasion and metastasis; iii)
deregulated cellular metabolism; and iv) genetic instabil-
ity and mutations.
Chronic IGF1R activation of the MG results in tumors with
a ‘sustained growth signaling’ signature
Proliferative signaling is normally a highly regulated
process. In a tumor, the replicative cell homeostasis is
deregulated causing sustained growth signaling [9]. Since
mice were chronically exposed to insulin analogues that
activate (to a lesser or greater extent) the IGF1R, we
postulated that the decreased tumor latency time (after
X10/IGF1 stimulation) would be a direct result of an up-
regulated IGF1R signaling pathway. We incorporated
mouse orthologs of all human genes (~60 genes) that
are directly involved in “INSR and IGF1R signaling” ac-
cording to Ingenuity Pathway Analysis (IPA) (Fig. 2a). A
hierarchical clustering analysis was performed for all 50
MG tumors on the relative expression levels of these
genes (Fig. 2b). Two clusters could be defined. In cluster
1, tumors from low mitogenic treatments are enriched,
whereas cluster 2 predominantly consists of the X10/
IGF1 (high mitogenic compound) treated tumors. These
two different clusters could not be linked to specific
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Fig. 1 (See legend on next page.)
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signaling pathways (e.g., PI3K, MAPK, JAK signaling
cascade).
To predict the proliferative potential of all the individ-
ual tumors, we next built an SVM classifier using tran-
scriptomic signatures associated with proliferation
(Fig. 2ci). No significant effect was observed; however, a
trend for the tumors in the IGF1 treatment groups to
have an increased proliferative potential could be seen.
As a positive control for the SVM simulation, similarly
we ran the SVM simulation on our earlier micro-array
data of the MCF7-IGF1R cells stimulated with the differ-
ent insulin analogues. We observed that 1 h after glar-
gine, X10, and IGF1 stimulation a strong and significant
proliferative genetic signature could be detected. These
results are in line with the proliferative potential as de-
termined with functional in vitro assays using this cell
line and insulin analogue exposures [5], which makes us
believe that the transcriptomic profiles and used SVM
simulation is predictive for the biological effect.
An effort was made to determine the growth rate of
the individual tumors by calculating the tumor vol-
ume from time of detection until the time of sacrifice
(data not shown). The EMT tumors in general were
highly proliferative resulting in a very small timeframe
(a couple of days to weeks) in which tumor volume
could be assessed. Unfortunately, this resulted in just
a few data points per tumor. Knowing that tumor
growth is very likely not linear during tumor develop-
ment we did not feel comfortable sharing these re-
sults. The proliferative potential was also assessed
with ki67 staining on several tumors, but as expected
there appeared to be a very small window and all
tested tumors had a ki67 score >45% indicative of be-
ing highly proliferative (data not shown). Next, we
attempted to isolate cells from each tumor; we antici-
pated that monitoring the growth rate of each mouse
mammary gland tumor-derived cell line would resem-
ble the growth rate of its originating tumor. Although
it appeared to be rather easy to generate a cell line
from each individual tumor, it was quite evident that
just a small subset of cells would grow out from
these tumors. We feared that this clonal expansion
would give a skewed image of true tumor growth,
and therefore we decided not to include these data.
Chronic IGF1R activation induces tumors with a more
mesenchymal phenotype and a higher migration
potential
Next, we assessed the hallmark “tissue invasion and
metastasis”. We calculated the average number of tu-
mors per mouse per treatment group. Interestingly, we
found a significantly higher number of tumors in the
IGF1 group (and a non-significant increase for the
chronic X10 and glargine treatment groups) compared
to the vehicle-treated mice (Additional file 1). This ef-
fect can be both due to an increased incidence of mul-
tiple primary tumors as well as an increased formation
of metastasis in the IGF1 group. To assess the under-
lying genetic pathways that might have induced metas-
tasis formation we incorporated all genes that are
directly associated with the EMT or the mesenchymal
to epithelial transition (MET) according to IPA. The
gene expression of the mouse orthologs of these genes
is presented in an unsupervised hierarchical clustering
(Fig. 3a). Two clear gene groups were observed: group
A containing genes associated with epithelial phenotype
(Elf5, Serpinb5, Cdh1, Grhl2, Elf3, and Wnt4), and
group B containing twelve genes associated with mes-
enchymal cells (Pdgfrb, Six1, Snai2, Tcf4, Zeb1, Klf8,
Wnt5a, Snail, Vim, Twist1, and Cdh2). From this hier-
archical clustering, three separate treatment clusters
could be discriminated. Cluster 1 consists of tumors
that show high expression of epithelial- and low expres-
sion of mesenchymal-associated genes; three out of six
tumors originate from the vehicle-treated animals.
Cluster 2 shows moderate expression levels of epithe-
lial- and mesenchymal-associated genes; interestingly
the majority of these tumors were from the glargine
treatment condition. Cluster 3 consists of tumors that
have a low expression of epithelial and high expression
of mesenchymal markers. IGF1 treatments were not
present at all in cluster 1 and 2, while IGF1 and X10
treatment groups were over-represented in cluster 3.
This suggests that IGF1R-mediated signaling is a driver
of tumors with an EMT phenotype. We substantiated
the phenotypes for the three different clusters (Fig. 3b).
The tumors in cluster 1 predominantly expressed epi-
thelial cells that contain many E-cadherin-positive cells.
Tumors of the cluster 2 and 3 phenotype were
(See figure on previous page.)
Fig. 1 Experimental overview. a Overview of the chronic insulin analogue exposure experiment. b The Kaplan-Mayer MG tumor-free mice plots
with the median tumor latency per treatment group; the colored dots indicate the selected tumors for the transcriptomic analysis. c the insulin-
like growth factor-1 receptor (igf1r), A isoform of the insulin receptor (ira), and B isoform of the insulin receptor (irb) gene expression levels in MG
tissue of young mice (8 weeks), old mice (~50 weeks), and in MG tumors (first graph); the second plot (right) shows the receptor gene expression
distribution in the MG tumor tissue of mice chronically exposed to different insulin analogues. d Heat map of the next-generation sequencing
data showing hierarchical sample clustering by sample-to-sample distance; the lower table shows the Spearman rank correlation coefficients
within the treatment groups (bold) and the coefficient between the different treatment groups (averaged per condition). e The hallmarks of
cancer with the features highlighted that we will discuss in view of the chronic insulin analogue exposure experiment. **P < 0.01, ***P < 0.001.
ns not significant. (Adapted from Hanahan and Weinberg [9])
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characterized as EMT tumors predominantly consisting of
mesenchymal cells, lack of E-cadherin staining, and clear
smooth muscle actin (SMA) staining (data not shown) [7].
To link the transcriptomics data further to the
phenotype we performed a SVM simulation to derive
predictions for the cell migratory potential of each
tumor (Fig. 3ci). Overall, no significant difference in
the migration potential was observed for the different
treatment groups; potentially the intrinsic high vari-
ation of in vivo experiments and smaller group sizes
can explain lack of power in this analysis. To evaluate
whether IGF1 signaling itself is a strong activator in
vitro, we also applied our SVM classifier to our previ-
ous MCF7-IGF1R transcriptomics data exposed to the
different insulin analogues (Fig. 3cii). IGF1, X10, and
glargine caused a significant increase in the migration
potential. Altogether, these data suggest that chronic
exposure to X10, and especially IGF1, induces tumors
with a more mesenchymal phenotype that are possibly
more aggressive in terms of their migratory potential.
Mice receiving a chronic X10 and IGF1 treatment develop
tumors with a higher Warburg potential
Through the activation of the INSR, insulin and insulin
analogues directly affect cell metabolism. Therefore, we
wondered whether the chronic treatment with insulin
analogues induce tumors with a deregulated cellular me-
tabolism or a higher Warburg potential. To test this we
used all genes directly involved in “glycolysis” and in
“oxidative phosphorylation” according to IPA. An un-
supervised hierarchical clustering of the expression pro-
files of each tumor revealed two very clear gene groups
(Fig. 4a). Strikingly, the first gene group consists of
eleven genes that are all directly involved in glycolysis;
all the genes in the second cluster are involved in oxida-
tive phosphorylation. Four clear tumor clusters could be
detected: cluster 1 with high expression of glycolysis
genes and low expression of oxidative phosphorylation
genes; cluster 2 with moderate glycolysis; cluster 3 with
little glycolysis and moderate oxidative phosphorylation;
and cluster 4 with high oxidative phosphorylation and
little glycolysis. For the insulin group almost all tumors
were related to cluster 3 (little glycolysis and moderate
oxidative phosphorylation: 90%). For glargine-related tu-
mors, 70% showed enrichment for genes regulating oxi-
dative phosphorylation. IGF1 and X10 tumors showed
increased expression of genes involved in glycolysis (60%
and 50%, respectively) compared to the vehicle control.
This suggests that chronic insulin signaling drives tu-
mors in a more oxidative phosphorylation mode.
Since IGF1 and X10 were mostly related to glycolysis
we performed an independent bioinformatics analysis on
the activity of various metabolic processes. This revealed
several significantly down- and upregulated metabolic
programs in IGF1/X10-derived tumors compared to the
vehicle/insulin/glargine tumors (Fig. 4b). Importantly, as
expected, oxidative phosphorylation was significantly
downregulated in the IGF1/X10 group (P = 0.000107)
while glycolysis was significantly upregulated. Again, this
analysis was also performed on the microarray data of
MCF7-IGF1R cells exposed to the different insulin ana-
logues. Similar to the in vivo data, IGF1 and X10 treat-
ment significantly downregulated the citric acid cycle as
well as oxidative phosphorylation (both P < 0.0005) and
upregulated glycolysis (P < 0.00001) (Fig. 4c). These data
suggest that both IGF1 and X10 promote a Warburg ef-
fect in mammary gland tumors (chronic exposure) and
human tumor cell lines (a single 1 h exposure).
Biomass production rate is highly upregulated in tumors
of chronic X10/IGF1-treated mice
Tumor mice receiving a chronic X10 and IGF1 treat-
ment showed increased expression of glycolysis related
genes (Fig. 4) and are associated with a decreased tumor
latency time (Fig. 5a). We evaluated whether this differ-
ence in metabolic capacity is related to enhanced
growth. To test this hypothesis, we predicted the rate of
the accumulation of biomass in all these different tu-
mors based on the gene expression profiles of biomass-
producing metabolic processes. In Fig. 5b, a bar graph of
these results is presented. A highly increased mammary
gland tumor biomass production rate was observed in
chronic X10- and IGF1-treated tumors. This finding is
in agreement with the observed increased proliferative
potential in the X10/IGF1 tumors. We hypothesize that
the decreased tumor latency time by X10 and IGF1
treatment was caused by enhancing the tumor develop-
ment rather than interfering with the tumor initiation.
Ezh2 and Hras mutations are enriched in chronic IGF1R-
activated tumors
Since IGF1 and X10 promote cell proliferation, this could
lead to a manifestation of mutations and consequently
modulation of tumor development and progression. To
(See figure on previous page.)
Fig. 2 Sustained growth signaling in mammary gland tumor tissue of chronically insulin analogue exposed mice. a The INSR/IGF1R signaling
pathway with receptors, downstream targets, and the biological effect. b Hierarchical clustering (Euclidian distance) of the INSR/IGF1R-specific
gene expression per MG tumor. The pie diagrams show the distribution of the different treatments in the two clusters. c Bar graph of SVM
simulation on the predicted proliferation potential per treatment of MG tumors of the chronically exposed mice (i) and human breast cancer cells
(MCF7 IGF1R) exposed for 1 h to the indicated insulin analogue (ii). *P < 0.05. ns not significant
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evaluate if chronic IGF1 or X10 treatment affects the
number of mutations, a mutational analysis was per-
formed on all tumors based on the 40 million 100 base
pair reads for each tumor. The number of different muta-
tions was ~3000 mutations per tumor and no significant
difference between treatment groups could be detected.
Furthermore, there was no correlation between the num-
ber of mutations per tumor and the tumor latency time
(best fit correlation values, slope = 0.00001207, r2 =
0.0000099, P value = 0.9827) (Fig. 6a).
Next, we focused on specific clinically relevant muta-
tions that are part of the ~140 known human tumor
drivers according to Vogelstein and colleagues [10]. In the
50 mouse tumors that we sequenced, 102 of these tumor
drivers were mutated. On average, each tumor had about
35 of these tumor driver mutations and again it seems that
the chronic treatment did not affect the overall number of
tumor driver mutations per tumor (Fig. 6b). Also, for the
tumor driver mutations, there was no correlation between
the number of mutations and latency time of each tumor.
Furthermore, no treatment-specific effects could be de-
tected for the average number of point mutations, the
average number of frame shifts, the average number of
start CODON insertions, or the average number of stop
CODON insertions (Additional file 2).
We next determined the mutations that are over-
represented (>50%) in the X10/IGF1 treatments
(Fig. 6c). All mutations are involved in cancer devel-
opment and/or progression [10, 15]. Although no spe-
cific core pathway links these individual mutations,
strikingly Ezh2 and Hras were strongly over-
represented in IGF1/X10-treated tumors. In a similar
way we looked at specific mutations that have been over-
represented in insulin analogue treatment altogether and
highly under-represented in the vehicle condition. No
general mechanism was identified that could explain
the enrichment of these mutations in the treatment
groups. However, a set of five mutations was not de-
tected at all in the vehicle control, yet these were
specifically affected in the insulin treatment group.
Overall, these data suggest that the IGF1/X10 en-
hanced tumor formation is associated with several key
candidate cancer drivers that could contribute, includ-
ing Ezh2 and Hras which are known drivers in hu-
man breast cancer [16, 17].
Discussion
In this study, we used a next-generation sequencing-
based transcriptome analysis to characterize mammary
gland (MG) tumors from the p53R270H/+WAPCre
mouse model that were chronically exposed to
insulin-like molecules. We found indications that tu-
mors of mice that received chronic treatment of X10
or IGF1 (compounds with a high affinity towards the
IGF1R) show a transcriptomic profile that can be
linked to a phenotype with an increased growth po-
tential, enhanced migratory capabilities, and a higher
Warburg potential. Moreover, the candidate cancer
driver mutations in Ezh2 and Hras were highly
enriched in X10 and IGF1 tumors.
This is the first study in which a human relevant
breast cancer mouse model has been used to study the
tumorigenic effects of chronic insulin analogue treat-
ment. Eventually, all mice from this model developed
spontaneous MG tumors with a high human relevance.
In this way it was possible to compare tumors induced
by insulin analogue treatment with tumors induced by
chronic insulin or vehicle treatment. This is in contrast
to other studies using wild-type mice where only a few
tumors with an origin less relevant to the human situ-
ation could be evaluated [18, 19].
Tumors often have an increased IRA:IRB ratio [20, 21]
that can possibly influence the in vivo transformational
effects of insulin analogues [22]. We found that IRA
gene expression levels are upregulated (twofold) in pre-
neoplastic MGs compared to expression levels in normal
MGs, but IRA gene expression levels in tumors were
similar to that of normal MG tissue. This might indicate
that the IRA plays a stimulatory role in the transform-
ation of normal to neoplastic MG tissue, but once the
MG tumor is established the A isoform of the insulin re-
ceptor does not play a key role in proliferative signaling
anymore. Surprisingly, IRB gene expression levels were
strongly downregulated (over 10-fold) in MG tumors.
This suggests that the IRA:IRB ratio is indeed increased
in MG tumors, but this effect is mainly caused by down-
regulation of IRB expression levels rather than an upreg-
ulation of IRA.
We anticipated that chronic stimulation with insulin-
like molecules would decrease the Warburg potency, as
insulin deprivation in human fibroblasts led to an
(See figure on previous page.)
Fig. 3 Tissue invasion and metastasis in mammary gland tumor tissue of chronically insulin analogue exposed mice. a Hierarchical clustering
(Pearson correlation) of genes involved in epithelial to mesenchymal transition (EMT) or mesenchymal to epithelial transtition (MET) per MG
tumor. The pie diagrams show the distribution of the different treatments in the three clusters. b The E-cadherin/HOECHST immunofluorescent
hematoxylin and eosin (H&E) pathology slides of three example tumors showing epithelial or mesenchymal characteristics. c Bar graph of SVM
simulation on the predicted migration potential per treatment of MG tumors of the chronically exposed mice (i) and human breast cancer cells
(MCF7 IGF1R) exposed for 1 h to the indicated insulin analogue (ii). *P < 0.05. ns not significant
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Fig. 4 (See legend on next page.)
ter Braak et al. Breast Cancer Research  (2017) 19:14 Page 11 of 15
induction of anaerobic glycolysis [23]. Indeed, we saw
that 90% of the insulin-induced tumors showed an in-
creased oxidative phosphorylation response compared to
60% for the spontaneous vehicle-induced tumors. Inter-
estingly, we found that compounds that induced an
equi-glycemic response but with an increasing mitogenic
potential at the doses used in this study (insulin, glar-
gine, X10, and IGF1) [7] also showed an increasing per-
centage of tumors depending on anaerobic glycolysis
(10%, 30%, 50%, and 60%, respectively). This might sug-
gest that proliferative signaling is indirectly or directly
coupled to the Warburg effect. Tumor samples have de-
liberately been taken 24 h after the last injection, since
we were interested in the long-term rather than the
short-term in vivo effects. During this time the exogen-
ous compounds are fully degraded by enzymes and
therefore no short-term signaling effect of the com-
pounds can be observed [24, 25]. However, we cannot
fully exclude the effect of direct insulin analogue treat-
ment on tumor cell metabolism, since treatment of
MCF7-IGF1R cells with the various insulin analogues
also affected the glycolytic metabolic program.
Using the SVM model we could detect a sustained
proliferative signaling in the chronic X10/IGF1-treated
tumors which might suggest that chronic growth factor
treatment can transform tumors in such a way that an
autocrine growth factor signaling pathway is induced. A
likely explanation would be a differential mutational pat-
tern in cancer driver genes that underlie such a differen-
tial proliferative pathway. Chronic insulin, glargine, X10,
or IGF1 treatment did not result in more mutations, and
no correlation could be detected with the number of
mutations or tumor latency time. Interestingly several
X10/IGF1-enriched mutations were observed, including
Ezh2, Hras, and Traf7, of which Ezh2 and Hras are
prominent modulators of human breast cancer. It is pos-
sible that these specific mutations contribute (in)directly
to the X10/IGF1 phenotypes and enhanced tumor devel-
opment and progression. Since we have only performed
RNAseq we can, of course, not exclude other genomic
mutations that were missed in our analysis and that
could contribute to MG tumor development and explain
the IGF1R-driven enhancement of tumor development/
progression in our models.
Conclusions
Altogether our data suggest that the observed decreased
tumor latency time in the p53R270H/+WAPCre mouse
model after chronic X10/IGF1 treatment is a result of an
enhanced tumor biomass production rate. Furthermore,
these treatments might facilitate tissue invasion and me-
tastasis and deregulate the cellular metabolism in the
tumor. All these factors contribute to an enhanced tumor
development, thus decreasing the MG tumor latency time
in this model. We did not find any evidence that chronic
glargine treatment induced a more aggressive tumor
phenotype or increased the biomass production rate, but a
slight increased Warburg potential was observed com-
pared to tumors induced by insulin treatment.
(See figure on previous page.)
Fig. 4 Warburg effect in mammary gland tumor tissue of chronically insulin analogue treated mice. a Hierarchical clustering (Pearson correlation)
of genes involved in glycolysis or oxidative phosphorylation per MG tumor. The pie diagrams show the distribution of the different clusters per
treatment group. b Table with the metabolic pathways that were significantly down- or upregulated in the X10/IGF1 treatment groups compared
to the vehicle, insulin, and glargine treatment groups. c Table with the metabolic pathways that were significantly down- or upregulated after
X10/IGF1 exposure compared to vehicle, insulin, and glargine treatment in the MCF7 IGF1R model
Fig. 5 Predicted biomass production rate is increased in tumors of chronically X10/IGF1-treated mice and could possible explain the decreased
tumor latency time in these treatments. a Bar plot of the mean tumor latency time in weeks per chronic treatment. b Bar plot of the normalized
biomass production rate per treatment
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Fig. 6 Genetic instability in mammary gland tumor tissue of chronically insulin analogue-exposed mice. a The bar plot shows the average
number of mutations per MG tumor for all chronic treatments; the dot plot indicates that there is no correlation between the number of
mutations of a specific tumor and tumor latency time. b The same as in a, but here we focus on clinically relevant human tumor driver mutations.
c Some specific tumor driver mutations are featured in these bar plots. The first bar plot represents the mutations that are enriched in the X10/
IGF1 treatment groups; in the second bar plot, the mutations are highlighted that are under-represented in the vehicle treatment group. N shows
the number of tumors in which this specific mutation was present
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Additional files
Additional file 1: Average number of MG tumors increased in chronic
IGF1 treated mice. The average number of mammary gland tumors per
treatment group. (TIF 2642 kb)
Additional file 2: Chronic insulin analogue treatment does not affect
the mutational profile of the tumors. A) The average number of point
mutations per treatment group. B) The average number of frame shifts
per treatment. C) The average number of start CODON insertions per
treatment. D) The average number of stop CODON insertions per
treatment. (TIF 12348 kb)
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